A series of ureas was prepared by reacting mono-or di-isocyanates with 3-amino-1H-1,2,4-triazole derivatives. The new carboxamides were investigated as activators of two human (h) carbonic anhydrases (CAs, EC 4.2.1.1), the physiologically relevant isoforms hCA I and II, considering the fact that they have structural resemblance to histamine, a well-known CA activator. Highly effective activators were detected in the series, with potency in the low nanomolar and subnanomolar range, depending on the substitution pattern at the 1,2,4-triazole ring and the nature of the linker between the two heterocyclic rings, in the case of the diureas. The most effective hCA II activator (K A of 0.05 nM) ever reported has been evidenced in this study. Although CA activators do not have pharmacological applications for the moment, in animal models it has been shown that they enhance cognition, making them interesting for conditions in which CA activity is diminished, such as aging or Alzheimer's disease.
Introduction
The carbonic anhydrases (CAs, EC 4.2.1.1) represent a superfamily of metalloenzymes, with seven different genetic families known to date, the a-, b-, c-, d-, f-, g-and h-CAs, all of the which efficiently catalyze the reaction between CO 2 and water, with formation of bicarbonate and protons. [1] [2] [3] [4] The inhibition and activation of CAs are well-understood processes: most types of classical inhibitors bind to the metal center within the enzyme active site, [5] [6] [7] [8] [9] [10] [11] whereas the activators bind at the entrance of the active site cavity and participate in proton shuttling processes between the metal ion -bound water molecule and the environment. 12, 13 This leads to enhanced formation of the metal hydroxide, catalytically active species of the enzyme. The most studied class is surely a-CAs, which are expressed widespread in humans and mammals, and is composed by 16 isoforms that also possess esterase or thioesterase activity. 2 Aberrant expression or activation of some isoforms of a-CAs is associated to a number of human diseases, among which cancer is surely the most prominent. 1,3 Accordingly, the design and development of small molecules able to inhibit CAs functions in vitro and in vivo has represented a valuable opportunity in drug discovery. 1, 4 A number of CA inhibitors (CAIs) are available in the drug market for the therapy of glaucoma, 5 such as the sulfonamides dorzolamide, methazolamide and acetazolamide, 1b,1c,6 this latter being the most widespread CAI used also with other therapeutic indications such as diuretic and antiepileptic. However, these drugs are pan-CAs inhibitors and the systemic administration is generally associated to adverse off-target effects. Nowadays the development of CAIs is facilitated by the advances recorded in biotechnology, structural biology, computational modeling and organic chemistry, which offer the valuable opportunity to investigate multiple chemotypes as CAIs and to characterize the atomic details of their interaction with the target enzymes.
1b,7
In recent years, particular attention and interest have been captured by the identification, structural characterization and understanding of the physiological and pharmacologic roles that CA activators may play. [12] [13] [14] Only in 1997 we reported the first Xray crystal structure of an activator bound to the human (h) CA isoform hCA II. 12b This activator was histamine, and was found bound at the entrance of the CA active site cavity, with the imidazole moiety participating in shuttling protons between the active site and the bulk solvent, thus acting as a second proton shuttle of the enzyme in addition to His64, whereas the amino group from the aminoethyl moiety of histamine did not participate in any interaction with the enzyme active site. This was the reason why many histamine derivatives in which the aliphatic amine was chemically modified were thereafter investigated as CA activators 
Results and discussion

Drug design of the new CAAs
Histamine (HST), the first CAA for which the binding has been revealed by using X-ray crystallography (in adduct with isoform hCA II) has been used as lead compound.
12b
Derivatives 1-14 were prepared as shown in Scheme 1, incorporate 1,2,4-triazole instead of the imidazole moiety present in HST, as well as amino or COOH moiety able to participate in proton transfer processes.
12-14
Derivatives with one heterocyclic ring (1-3) as well as derivatives with two such moieties (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) were obtained, in order to investigate a possible cooperativity effect between the two moieties with proton transferring capacity. The other fragments present in these molecules (moieties R and R 0 ) are alkyl, alkylene, cycloalkyl, aryl, etc., and were introduced in order to have different linkers of variable length between the two heterocyclic rings (in [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] as well as for modulating lipophilicity and potentially the interaction with the enzyme active site (in all these derivatives). An ureido linker connected the two fragments of these molecules (the heterocycle and the lipophilic tails) since it was been reported that such a moiety assures an appropriate degree of flexibility for the modulator of activity bound within the CA active site.
12-15
Compounds 1-14 were obtained by a routine chemistry, i.e., reaction of isocyanates/di-isocyanates with the appropriate 1,2,4-triazole derivative (Scheme 1). Compound 5 has been previously reported. 16 It forms stable helical pores in lipid bilayers. Experimental assays revealed that the T-channel with the hydrated carbonyl and amine moieties pointing toward the T-channel center and surrounding the transport direction, presents moderated water permeability and large open ion-conductance states.
Activation of hCA I and II with compounds 1-14
The activator-binding site within the CA active cavity was a rather controversial issue till 1997, when the first X-ray crystal structure of an activator bound to CA II was reported, i.e., the hCA II -histamine adduct.
12b Thereafter, many other CAactivator adducts were reported and investigated by high resolution X-ray crystallography, being shown that they bind within the same part of the active site, i.e., at its entrance. 12 In this way, through protonatable moieties found in their molecules they participate to supplementary shuttling processes of protons between the enzyme active site and the environment, facilitating the formation of the zinc hydroxide, nucleophilic species of the enzyme. Surprisingly, in 2009 we have reported that coumarins, such as derivative 15a (Scheme 2), a natural product isolated from an Australian plant, 17 act as CA inhibitors, but their binding site within the CA enzyme cavity is the same as the activator binding site evidenced earlier (Fig. 1) . 12, 17 In fact, the coumarin 15a is hydrolyzed within the CA active site to the 2-hydroxy-cinnamic acid derivative 15b, which has been observed bound in the activator -binding site, as illustrated in Fig. 1 , where two CA activators adducts (histamine and L-adrenaline) were superposed on the hCA II -coumarin X-ray crystal structure. 17 Thus, the entrance of the CA active site may accommodate both activators as well as inhibitors: the difference between the two classes of modulators is that the activators must incorporate protonatable moieties which may participate in proton shuttling processes, similar to His64. Thus, the designed CAAs reported here, 1-14, synthesized by using histamine as lead, were investigated kinetically for their interaction with the physiologically relevant isoforms hCA I and II, (Table 1) . Histamine (HST) has been used as a standard activator in these experiments, although this compound is not a highly effective CAA (it has a K A of 2 lM against hCA I and of 125 lM against hCA II). 12b The following structure activity relationship (SAR) can be evidenced from the activation data of Table 1: (i) All synthesized compounds 1-14 showed effective hCA I activating properties, with activation constants ranging between 0.81 and 993 nM. Both mono-ureas (1-3) as well as bis-derivatives (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) showed good such properties. For this first subseries the SAR is quite straightforward, with the butyl-derivative 1 being a low nanomolar activator (K A of 6.1 nM), whereas the longer chain compounds showed a progressive decreasing activity with the increase of the R from C4 to C18 (Table 1) . For bis-derivatives 4-14, the SAR seems to be more complex. Thus, for the compounds with an alkyl linker 8and amino moieties), 4-7, activity is in the 11.1-982 nM range, with the best K A for the compounds with a C8 linker (derivative 6). Thus, the activating properties increase from C4 to C6 and then to the C8-linker derivative, whereas a longer linker as in 7 (C12) leads to a strong decrease of the CA activating properties. The compound incorporating COOH instead of amino moieties as the heterocyclic ring, 8, was also an effective hCA I activator (K A of 13.7 nM), comparable or even slightly better than the corresponding derivative incorporating amino groups, 5. The compound with a cycloalkyl linker, 9, was not very active as a CAA, probably due to the rather bulky nature of the linker. However, some of the aromatic linkers present in derivatives 10-144 led to highly effective CAAs against isoform hCA I, such as derivatives 11, 12 and 13 (K A s of 0.81-4.2 nM, Table 1 ). Thus, the derivative with 1,4-phenylene linker (10) was moderately active (K A of 65 nM) whereas the one with the 1,3-phenylene linker, 11, had an increased activity (K A of 4.2 nM). The biphenylene and methyl-biphenylene linkers however were those which led to the best hCA I activators, compounds 12 and 13, with activation constants in the subnanomolar range. However the presence of additional substituents at the biphenylene ring, as in 14, led to a drastic reduction of the activating properties. Thus, for this series of mono-or di-urea derivatives incorporating 1,2,4-triazole rings and amino/carboxy moieties as proton transfer groups, activity was primarily influenced by the nature of the R moiety for the mono-ureas or the linker between the two heterocyclic ring for the di-urea derivatives. (ii) The physiologically dominant isoform hCA II was also effectively activated by most derivatives investigated here, with activation constants ranging between 0.05 and 6700 nM (Table 1) . SAR was rather similar with what mentioned above for hCA II in the case of the mono-ureas 1-3, with the best hCA II activator being the compound with the shorter tail, 1 (K A of 1.7 nM) whereas activity progressively decreased with the increase of the R length from C4 to C18, in derivatives 2 and 3. For the bis-derivatives with alkyl spacers, the best activity was observed for 5 (incorporating a C6 linker) whereas the structurally related congeners with shorter (4) or longer (6 and 7) linkers showed a similar activating profile, with activation constants of 65-91 nM. However, unlike the situation of hCA I, the carboxylic acid 8 was a very poor hCA II activator, with a K A of 6700 nM. The same was true for the bis-amine 9, incorporating a cycloalkyl linker, with a KA of 1570 nM (Table 1) . SAR was also rather
CA-mediated hydrolysis
Scheme 2. CA-mediated hydrolysis of coumarin 15a to the 2-hydroxycinnamic acid derivative 15b. complicated for the compounds with aromatic linkers, 11-14. Thus 11, with a 1,4-phenylene linker was highly effective as hCA II activator, with a KI of 0.12 nM, whereas the congener with 1,3-phenylene linker lost activity being weakly effective (K A of 826 nM). The activity was again good for the biphenylene-linker derivative 12 (K A of 14.1 nM) and excellent, probably the best hCA II activator ever reported, for 13, with a methylene-biphenylene linker and a KA of 0.05 nM (Table 1) . Additional moieties on the linker, such as in 14, were again detrimental to the hCA II activating properties. (iii) The activating profile of these compounds for the two CA isoforms were in general similar, although some compounds do show some isoform selectivity. For example, 8 was hCA I -selective as an activator, whereas 10 was rather hCA IIselective. Compounds such as 1 or 13 were highly effective activators of both isoforms.
Conclusions
In conclusion, in a small series of ureas/di-ureas incorporating 1,2,4-triazole substituted with amino or carboxyl groups as proton shuttling moieties, highly efficient activators of the physiologically relevant isoforms hCA I and II were evidenced. hCA I was activated with activation constants ranging between 0.81 and 993 nM, whereas hCA II with activation constants ranging between 0.05 and 6700 nM. The substitution pattern at the 1,2,4-triazole ring and the nature of the linker between the two heterocyclic ring in the case of the disubstituted compounds were the factors influencing the CA activating properties of these compounds. The most effective hCA II activator (K A of 0.05 nM) ever reported has been evidenced in this study. This may be relevant for finding clinical candidates for investigating the role of CA activation in cognitive impair or other diseases characterized by a CA I/II deficit, such as Alzheimer's disease or aging.
Experimental protocols
Chemistry
All compounds have been synthesized following the general procedure described below. The amine (30 mmol) was mixed with the corresponding amount of isocyanate, under sonication (1 eq.: 1 eq. for the monourea compounds and 2 eq.: 1 eq. for the bis-urea compounds). The mixture was solubilized in 10 ml of THF (tetrahydrofuran), 5 ml of ethyl acetate, and 10 ml of dimethylacetamide. The reaction mixture was heated to 120°C for 15 min. When the precipitation begins 5 ml of acetonitrile are added and the heating is maintained for another hour. The resulting product will be a white powder which is then filtered and washed with methanol on the filter paper. The exceptions of the protocol are compounds 1 and 4 for which the reaction temperature is 60°C and compounds 2 and 5 for which the reaction temperature is 80°C. Compound 1 is soluble in the reaction mixture and therefore the purification procedure is as follows. The reaction mass is evaporated under vacuum in a round bottomed flask and the compound is then recrystallized from CHCl 3. Alternatively a microwave reactor has been used. The procedure is the following: the isocyanate is dissolved in 5 ml of acetonitrile and added over the amine in the microwave reactor. The reaction is performed at 140°C under high stirring for 15 min. The product is then filtered and washed with methanol. In the case of compounds 1a and 4 the temperature is 50°C and for compounds 2 and 5 is 90°C. For compound 1 the purification method is the same. All reagents were obtained from Aldrich and used without further purification. All organic solutions were routinely dried by using sodium sulfate (Na 2 SO 4 
Carbonic anhydrase activation assay
An SX.18MV-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic/inhibition of various CA isozymes as reported by Khalifah. 18 The CA-catalysed CO 2 hydration reaction was followed for a period of 5-10 s. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM HEPES (pH 7.4) as buffer and 0.1 M NaClO 4 for maintaining constant the ionic strength (these anions are not inhibitory in the used concentration). Saturated CO 2 solutions in water at 25°C were used as substrates. Stock solutions of activators were prepared at a concentration of 10 mM (in the assay buffer) and dilutions up to 0.01 nM done with the same assay buffer. Activator and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the enzyme-activator complex. The activation constant (K A ), defined similarly with the inhibition constant K I , 5-8 can be obtained by considering the classical Michaelis-Menten equation (Eq. (1)), which has been fitted by non-linear least squares by using PRISM 3: 
where v 0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator. [12] [13] [14] [15] The CA isoforms were recombinant ones, and were prepared in-house as reported earlier.
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